Recently, the KEYNOTE-689 trial investigated the incorporation of neoadjuvant and adjuvant pembrolizumab (anti-PD-1) into standard care for patients with locally advanced HNSCC (LA-HNSCC) (25). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.